|
Re: BIO Investor Forum, Oct 22-23
|
4
|
Zenith Epigenetics
|
Oct 23, 2019 06:38PM
|
|
Re: BIO Investor Forum, Oct 22-23
|
5
|
Resverlogix Corp.
|
Oct 23, 2019 10:56AM
|
|
Re: Secondary endpoints
|
5
|
Resverlogix Corp.
|
Oct 22, 2019 09:34PM
|
|
Re: BIO Investor Forum, Oct 22-23
|
3
|
Resverlogix Corp.
|
Oct 22, 2019 04:48PM
|
|
Re: Biogen looks to FDA for approval of early Alzheimers drug.
|
3
|
Resverlogix Corp.
|
Oct 22, 2019 11:09AM
|
|
Re: Aducanumab and the amyloid beta hypothesis is not dead yet!
|
1
|
BIOASIS TECHNOLOGIES INC
|
Oct 22, 2019 10:52AM
|
|
Re: Biogen looks to FDA for approval of early Alzheimers drug.
|
3
|
Resverlogix Corp.
|
Oct 22, 2019 10:51AM
|
|
Re: Biogen looks to FDA for approval of early Alzheimers drug.
|
3
|
Resverlogix Corp.
|
Oct 22, 2019 10:08AM
|
|
Aducanumab and the amyloid beta hypothesis is not dead yet!
|
1
|
BIOASIS TECHNOLOGIES INC
|
Oct 22, 2019 09:09AM
|
|
Re: Biogen looks to FDA for approval of early Alzheimers drug.
|
3
|
Resverlogix Corp.
|
Oct 22, 2019 09:02AM
|
|
Re: BIO Investor Forum, Oct 22-23
|
6
|
Zenith Epigenetics
|
Oct 18, 2019 01:01PM
|
|
Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
|
6
|
Zenith Epigenetics
|
Oct 18, 2019 12:56PM
|
|
Re: Reata, Friedreich’s Ataxia and Kidney Disease
|
3
|
Resverlogix Corp.
|
Oct 18, 2019 06:58AM
|
|
Re: Reata, Friedreich’s Ataxia and Kidney Disease
|
4
|
Resverlogix Corp.
|
Oct 17, 2019 10:55PM
|
|
Re: Reata, Friedreich’s Ataxia and Kidney Disease
|
8
|
Resverlogix Corp.
|
Oct 17, 2019 09:50PM
|
|
Roche Brain Shuttle Enters Clinical Trials
|
2
|
BIOASIS TECHNOLOGIES INC
|
Oct 17, 2019 03:04PM
|
|
Re: BIO Investor Forum, Oct 22-23
|
4
|
Zenith Epigenetics
|
Oct 17, 2019 02:41PM
|
|
BIO Investor Forum, Oct 22-23
|
6
|
Resverlogix Corp.
|
Oct 17, 2019 02:37PM
|
|
Re: Happy Thanksgiving all....
|
4
|
Resverlogix Corp.
|
Oct 15, 2019 04:03PM
|
|
Re: Happy Thanksgiving all....
|
5
|
Resverlogix Corp.
|
Oct 15, 2019 06:28AM
|
